# Corbus Pharmaceuticals Holdings, Inc.: financial statements, quarterly

CRBP · Nasdaq · CIK 1595097 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crbp.md) · [Financials](/companies/crbp/financials.md) · [Filings](/companies/crbp/filings.md) · [Insiders](/companies/crbp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crbp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [6.6](/filings/0000950170-24-123486.md) | [7.0 d](/filings/0000950170-25-037335.md) | [5.8](/filings/0000950170-25-064507.md) | [6.9](/filings/0000950170-25-103118.md) | [10.8](/filings/0001193125-25-277748.md) | [8.8 d](/filings/0001193125-26-098530.md) | [15.6](/filings/0001193125-26-219707.md) | [15.2](/filings/0001193125-26-338274.md) | [20.9](/filings/0001193125-25-277748.md) | [18.4 d](/filings/0001193125-26-098530.md) | [19.8](/filings/0001193125-26-219707.md) | [31.2](/filings/0001193125-26-338274.md) |
| Operating income | $m | [(9.5)](/filings/0000950170-24-123486.md) | [(10.1) d](/filings/0000950170-25-037335.md) | [(9.6)](/filings/0000950170-25-064507.md) | [(11.0)](/filings/0000950170-25-103118.md) | [(15.5)](/filings/0001193125-25-277748.md) | [(12.6) d](/filings/0001193125-26-098530.md) | [(19.8)](/filings/0001193125-26-219707.md) | [(19.2)](/filings/0001193125-26-338274.md) | [(24.4)](/filings/0001193125-25-277748.md) | [(22.0) d](/filings/0001193125-26-098530.md) | [(24.3)](/filings/0001193125-26-219707.md) | [(36.2)](/filings/0001193125-26-338274.md) |
| Interest expense | $m | [1.0](/filings/0000950170-24-123486.md) | [0.9 d](/filings/0000950170-25-037335.md) | [0.8](/filings/0000950170-25-064507.md) | [0.7](/filings/0000950170-24-091922.md) | [0.4](/filings/0001193125-25-277748.md) | [0.0 d](/filings/0001193125-26-098530.md) | [0.0](/filings/0000950170-25-064507.md) | [0.0](/filings/0000950170-25-103118.md) | [0.0](/filings/0001193125-25-277748.md) | [0.0 d](/filings/0001193125-26-098530.md) | not reported | not reported |
| Net income | $m | [(10.1)](/filings/0000950170-24-123486.md) | [(8.0) d](/filings/0000950170-25-037335.md) | [(6.9)](/filings/0000950170-25-064507.md) | [(10.0)](/filings/0000950170-25-103118.md) | [(13.8)](/filings/0001193125-25-277748.md) | [(9.5) d](/filings/0001193125-26-098530.md) | [(17.0)](/filings/0001193125-26-219707.md) | [(17.7)](/filings/0001193125-26-338274.md) | [(23.3)](/filings/0001193125-25-277748.md) | [(20.6) d](/filings/0001193125-26-098530.md) | [(23.0)](/filings/0001193125-26-219707.md) | [(35.0)](/filings/0001193125-26-338274.md) |
| Diluted EPS | $ per share | [(2.27)](/filings/0000950170-24-123486.md) | not reported | [(0.83)](/filings/0000950170-25-064507.md) | [(0.90)](/filings/0000950170-25-103118.md) | [(1.15)](/filings/0001193125-25-277748.md) | not reported | [(1.39)](/filings/0001193125-26-219707.md) | [(1.44)](/filings/0001193125-26-338274.md) | [(1.90)](/filings/0001193125-25-277748.md) | not reported | [(1.23)](/filings/0001193125-26-219707.md) | [(1.81)](/filings/0001193125-26-338274.md) |
| Basic EPS | $ per share | [(2.27)](/filings/0000950170-24-123486.md) | not reported | [(0.83)](/filings/0000950170-25-064507.md) | [(0.90)](/filings/0000950170-25-103118.md) | [(1.15)](/filings/0001193125-25-277748.md) | not reported | [(1.39)](/filings/0001193125-26-219707.md) | [(1.44)](/filings/0001193125-26-338274.md) | [(1.90)](/filings/0001193125-25-277748.md) | not reported | [(1.23)](/filings/0001193125-26-219707.md) | [(1.81)](/filings/0001193125-26-338274.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.2](/filings/0000950170-23-060377.md) | [13.7](/filings/0000950170-25-037335.md) | [14.1](/filings/0000950170-24-054625.md) | [23.7](/filings/0000950170-24-091922.md) | [19.4](/filings/0000950170-24-123486.md) | [17.2](/filings/0001193125-26-098530.md) | [18.9](/filings/0000950170-25-064507.md) | [20.0](/filings/0000950170-25-103118.md) | [27.0](/filings/0001193125-25-277748.md) | [28.5](/filings/0001193125-26-338274.md) | [25.7](/filings/0001193125-26-219707.md) | [23.4](/filings/0001193125-26-338274.md) |
| Current assets | $m | [31.2](/filings/0000950170-23-060377.md) | [23.5](/filings/0000950170-25-037335.md) | [122](/filings/0000950170-24-054625.md) | [148](/filings/0000950170-24-091922.md) | [161](/filings/0000950170-24-123486.md) | [153](/filings/0001193125-26-098530.md) | [137](/filings/0000950170-25-064507.md) | [123](/filings/0000950170-25-103118.md) | [108](/filings/0001193125-25-277748.md) | [167](/filings/0001193125-26-338274.md) | [144](/filings/0001193125-26-219707.md) | [123](/filings/0001193125-26-338274.md) |
| Total assets | $m | [36.3](/filings/0000950170-23-060377.md) | [28.3](/filings/0000950170-25-037335.md) | [126](/filings/0000950170-24-054625.md) | [152](/filings/0000950170-24-091922.md) | [164](/filings/0000950170-24-123486.md) | [156](/filings/0001193125-26-098530.md) | [140](/filings/0000950170-25-064507.md) | [125](/filings/0000950170-25-103118.md) | [110](/filings/0001193125-25-277748.md) | [168](/filings/0001193125-26-338274.md) | [144](/filings/0001193125-26-219707.md) | [127](/filings/0001193125-26-338274.md) |
| Current liabilities | $m | [31.5](/filings/0000950170-23-060377.md) | [31.9](/filings/0000950170-25-037335.md) | [25.9](/filings/0000950170-24-054625.md) | [24.0](/filings/0000950170-24-091922.md) | [11.6](/filings/0000950170-24-123486.md) | [11.8](/filings/0001193125-26-098530.md) | [11.6](/filings/0000950170-25-064507.md) | [13.3](/filings/0000950170-25-103118.md) | [17.1](/filings/0001193125-25-277748.md) | [20.7](/filings/0001193125-26-338274.md) | [18.1](/filings/0001193125-26-219707.md) | [21.5](/filings/0001193125-26-338274.md) |
| Total liabilities | $m | [36.0](/filings/0000950170-23-060377.md) | [35.2](/filings/0000950170-25-037335.md) | [28.8](/filings/0000950170-24-054625.md) | [26.4](/filings/0000950170-24-091922.md) | [13.7](/filings/0000950170-24-123486.md) | [13.5](/filings/0001193125-26-098530.md) | [12.8](/filings/0000950170-25-064507.md) | [14.1](/filings/0000950170-25-103118.md) | [17.4](/filings/0001193125-25-277748.md) | [20.7](/filings/0001193125-26-338274.md) | [18.1](/filings/0001193125-26-219707.md) | [24.7](/filings/0001193125-26-338274.md) |
| Long-term debt | $m | [0.0](/filings/0000950170-23-060377.md) | [0.0](/filings/0000950170-24-054625.md) | [0.0](/filings/0000950170-24-054625.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [17.8](/filings/0000950170-23-060377.md) | [15.9](/filings/0000950170-24-054625.md) | [12.8](/filings/0000950170-24-054625.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [0.3](/filings/0000950170-24-123486.md) | [(6.9)](/filings/0001193125-26-098530.md) | [97.0](/filings/0000950170-25-103118.md) | [126](/filings/0001193125-25-277748.md) | [150](/filings/0001193125-25-277748.md) | [142](/filings/0001193125-26-338274.md) | [127](/filings/0001193125-26-338274.md) | [111](/filings/0001193125-26-338274.md) | [92.1](/filings/0001193125-25-277748.md) | [148](/filings/0001193125-26-338274.md) | [126](/filings/0001193125-26-338274.md) | [102](/filings/0001193125-26-338274.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.2) d](/filings/0000950170-24-123486.md) | [(6.0) d](/filings/0000950170-25-037335.md) | [(8.0)](/filings/0000950170-25-064507.md) | [(8.9) d](/filings/0000950170-25-103118.md) | [(13.9) d](/filings/0001193125-25-277748.md) | [(10.9) d](/filings/0001193125-26-098530.md) | [(16.4)](/filings/0001193125-26-219707.md) | [(16.6) d](/filings/0001193125-26-338274.md) | [(15.6) d](/filings/0001193125-25-277748.md) | [(15.9) d](/filings/0001193125-26-098530.md) | [(25.6)](/filings/0001193125-26-219707.md) | [(29.6) d](/filings/0001193125-26-338274.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-23-060377.md) | [0.0 d](/filings/0000950170-24-030133.md) | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-219707.md) | [0.0 d](/filings/0001193125-26-338274.md) | not reported | not reported | [0.0](/filings/0001193125-26-219707.md) | [0.0 d](/filings/0001193125-26-338274.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.2](/filings/0000950170-23-060377.md) | [4.2](/filings/0000950170-24-054625.md) | [4.3](/filings/0000950170-24-091922.md) | [4.4](/filings/0000950170-24-123486.md) | [8.3](/filings/0000950170-25-064507.md) | [11.1](/filings/0000950170-25-103118.md) | [12.0](/filings/0001193125-25-277748.md) | [12.2](/filings/0001193125-26-219707.md) | [12.2](/filings/0001193125-26-338274.md) | [12.3](/filings/0001193125-25-277748.md) | [18.7](/filings/0001193125-26-219707.md) | [19.4](/filings/0001193125-26-338274.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,341,293 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338274.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.